Business Description
Zymeworks is a Delaware-based biotechnology company focused on developing advanced treatments for cancer, inflammation, and autoimmune diseases. Its pipeline includes several promising drug candidates targeting hard-to-treat cancers such as breast, ovarian, prostate, and lung cancer, with its lead product Ziihera already approved for patients with HER2-expressing tumors. The company has built proprietary technologies that allow it to engineer highly targeted antibodies and drug conjugates designed to attack cancer cells more precisely while minimizing harm to healthy tissue. Zymeworks works alongside major pharmaceutical partners including Bristol-Myers Squibb, GlaxoSmithKline, Daiichi Sankyo, and Janssen Biotech to advance its research and bring new treatments to patients.
